Anticoagulant treatment is associated with a reduction in mortality in patients with severe forms of COVID-19 and suffering from coagulopathy
The key points :
- Retrospective study of patients admitted with severe SARS-CoV-2 infection to Tongji Hospital (Wuhan) between January 1 and February 13, 2020.
- Mortality at 28 days was compared between a group of patients treated with anticoagulant (low molecular weight heparins (LMWH) or unfractionated heparin (UFH)) and an untreated group.
- Mortality at 28 days was reduced in patients treated with anticoagulant and who had a SIC (Sepsis Induced Coagulopathy) score ≥ 4 or a D-dimer level > 3.0 ug/mL.
- Le traitement anticoagulant semble être associé à un meilleur pronostic chez les patients présentant une infection sévère à SARS-CoV-2 avec une coagulopathie.
Reference :
1. TANG, Ning, BAI, Huan, CHEN, Xing, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 2020.
